Anastrozole · Cost-effectiveness analysis · Cost-utility analysis · Incremental cost-effectiveness ratio · Tamoxifen · QALY Summary Background: In the 'Arimidex', Tamoxifen Alone or in Combination (ATAC) trial, the aromatase inhibitor (AI) anastrozole had a significantly better efficacy and safety profile than tamoxifen as initial adjuvant therapy for hormone receptor-positive (HR+) early breast cancer (EBC) in postmenopausal patients. To compare the combined long-term clinical and economic benefits, we carried out a cost-effectiveness analysis (CEA) of anastrozole versus tamoxifen based on the data of the 100-month analysis of the ATAC trial from the perspective of the German public health insurance. Patients and Methods: A Markov model with a 25-year time horizon was developed using the 100-month analysis of the ATAC trial as well as data obtained from published literature and expert opinion. Results: Adjuvant treatment of EBC with anastrozole achieved an additional 0.32 quality-adjusted life-years (QALYs) gained per patient compared with tamoxifen, at an additional cost of D 6819 per patient. Thus, the incremental cost effectiveness of anastrozole versus tamoxifen at 25 years was D 21,069 ($ 30,717) per QALY gained. Conclusions: This is the first CEA of an AI that is based on extended follow-up data, taking into account the carryover effect of anastrozole, which maintains the efficacy benefits beyond therapy completion after 5 years. Adjuvant treatment with anastrozole for postmenopausal women with HR+ EBC is a cost-effective alternative to tamoxifen.
Introduction
InGermany,about57,000newcasesofbreastcanceraredi-agnosedeachyear,withanoverallbreastcancermortalityof 26.8% [1] . Tamoxifen is an established endocrine adjuvant treatmentforpostmenopausalwomenwithhormone-sensitive breast cancer [1, 2] . The use of tamoxifen as adjuvant treatmentreducesthe5-yearrelapseriskby41%andtheriskof death by 34% [3] . Furthermore, the risk of contralateral breast cancer is reduced by 39% [4, 5] . However, despite these improvements, many women still experience a recurrenceanddiefromthedisease.Moreover,tamoxifenhasbeen associatedwithserioussideeffects,suchasendometrialcancer [6] andthromboembolicdisorders [7] . Analternativeadjuvantendocrinetreatmentisanastrozole (Arimidex ® ;AstraZeneca,Wedel,Germany),athird-generation non-steroidal aromatase inhibitor (AI), which has consistently demonstrated superior efficacy and safety results comparedtotamoxifeninthe'Arimidex',TamoxifenAlone orinCombination(ATAC)trial [8, 9] .
The patient population in the ATAC trial consisted of postmenopausal women with estrogen and/or progesterone receptor-positive early breast cancer (EBC) who had completedprimarytherapy(surgery±radiotherapy±chemother-apy) and were eligible for adjuvant endocrine therapy. Patients were randomized to receive either anastrozole or tamoxifen(orboth)forupto5years [8] .Asthecombination armshowednobenefitovertamoxifenaloneintermsofefficacy or safety, this arm was discontinued following interim analysisat33months.Detailsofthedesign,methodologyand analysis of the trial have been published previously [8] . The present analysis focuses on the results of the two monotherapyarms,anastrozoleandtamoxifen,atamedianfollowupof100months.
Theseextendedfollow-updatashowedthat,comparedto tamoxifen, anastrozole was associated with significantly longerdisease-freesurvival(DFS)(hazardratio(HR)0.85, p = 0.003) and longer time to recurrence (TTR) (HR 0.76, p=0.0001) [9] .Recurrenceratesforanastrozole-treatedpatients remained significantly lower after treatment completion (HR 0.75, p = 0.01), indicating a carryover effect of anastrozolethatisevengreaterthanthatpreviouslyshown fortamoxifen [4] .Althoughoverallsurvival(OS)wasstatistically not significantly different in the hormone receptorpositive(HR+)patientgrouptherewerenumericallyfewer deaths (245 vs. 269) after recurrence in the anastrozole groupat100months [9] .
Anastrozole was also associated with a more favorable overall safety profile versus tamoxifen, e.g. a significantly lower incidence of endometrial cancer, thromboembolic events, and vaginal bleeding/discharge. Patients on anastrozoleshowedincreasedratesofarthralgiaandbonefractures during therapy [8, 10] ; however, no excess of fractures was notedafterthe5-yeartreatmentperiodwascompleted [9] . TheAmericanSocietyofClinicalOncology(ASCO)technologyassessmenthasrecommendedtheuseofAIseitheras initialtherapyoraftertamoxifentherapyforpostmenopausal womenwithHR+EBCaspartoftheoptimaladjuvanthor-monaltherapy [11, 12] .InGermany,nationalevidence-based recommendationsbytheWorkingCommitteeofGynecologicalOncology(ArbeitsgemeinschaftGynäkologischeOnkolo-gie(AGO)) [13] andtheofficialconsensusguidelinesbythe GermanCancerSociety(DeutscheKrebsgesellschaft(DKG)) [14] both recommend the use of AIs as adjuvant endocrine therapyforpostmenopausalwomenwithHR+EBC.
However, the higher acquisition cost of anastrozole, against a background of limited resources in several health systems,couldlimittheadoptionofthisagent.Germanyand Switzerland, for example, are closely following the USA in termsofhealthcareexpenses [15] .Overthecomingyears,demographicchangesincludingashifttoolderpatientpopulations and increasing rates of unemployment are expected to causeincreasedcostsandreducedcontributionstothehealth caresystemsofmanyindustrializedcountries.Thesedevelopmentsarelikelytohaveanimpactontheavailabilityandreimbursementofnewdrugsandonmedicaldecisionmaking.
Inordertoreachfullyinformeddecisions,treatmentchoices need to be supported by a systematic assessment of the costs andbenefitsofnewhealthtechnologies.Inmanycountries,independent institutions, like the National Institute of Clinical Excellence(NICE)intheUKortheInstituteforQualityand Efficiency in Health Care (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)) in Germany, havebeencommissionedtocarryouthealthtechnologyassessments(HTAs)onbehalfofthenationalhealthcaresystem.
Given the budgetary constraints of many health care systems, it is important to assess if anastrozole offers value for money, i.e. if anastrozole is cost effective compared to the currentstandardtreatment,tamoxifen.Theaimofthisstudy was to evaluate the long-term cost effectiveness of anastrozole compared with tamoxifen for postmenopausal women with HR+ EBC. The analysis was carried out from the perspectiveoftheGermanstatutoryhealthinsurance(Gesetzliche Krankenversicherung, GKV). It was based on the 100-monthanalysisoftheATACtrialinordertoevaluateforthe firsttimetheeconomicimpactofthelong-termclinicalbenefits(carryovereffect)ofanastrozoleinupfronttreatment.
Methods

Model Structure
To assess the cost effectiveness of anastrozole, a probabilistic Markov model was developed [16] . The model follows a hypothetical cohort of 1000postmenopausalwomen(meanage64years)withHR+EBCovera 25-yearperiod.A25-yeartimehorizonwaschosenforthemodelbecause oftheneedtocapturethelong-termbenefitsoftreatment.Alongertime horizonwouldhavehadverylittleimpactontheresultsconsideringaverage age at diagnosis and the life expectancy of postmenopausal women Cost-EffectivenessofAnastrozoleversus TamoxifeninGermany 159 observedinthecompletedtreatmentanalysisoftheATAC100trial [9] and on the durable treatment benefit previously observed with tamoxifen [3] .However,foraconservativeapproach,wealsoincluded an additional scenario with the same recurrence probabilities for tamoxifenandanastrozolebetweenyears9and10. -Duetothelackofpublisheddataonrecurrenceratesbeyond10years, therecurrenceratesbeyond10yearsareassumedtobethesamefor bothanastrozoleandtamoxifen. -TheresultsofautilitystudycarriedoutfortheUSA [18] areapplicable intheGermansetting. -MostAEsonlyoccurduringthe5-yeartreatmentperiod.Someserious AEscanoccurafterthisperiod(i.e.thromboembolicevents,endometrial cancer), and the relative risk goes back to the level of the nonbreastcancerpatientpopulationaftersometime(endometrialcancer, thromboemboliceventsanddeep-veinthromboembolism(DVT)after 0.5years,andhipfractureimmediately).
Model Inputs
Recurrences Informationoneventratesforrecurrenceanddeathwerederivedfrom the100-monthanalysisoftheATACtrial [9] .Inordertoextrapolatebeyond the 100-month follow-up period, parametric survival curves were fittedtobothtreatmentarms.Althoughthereareanumberofdistributionsthatcanbeusedtomodelsurvival [19] ,theWeibulldistributionis themostcommonasitdoesnotassumeaconstanthazardrateandisflexAdditionally,theanalysisisbasedonthefollowingassumptions: -TheATAC100datashowedacarryovereffectforanastrozoleextend-ingto9yearsbeyondtreatmentinitiation.Inlinewithearlierpublicationsandtoenablecomparisonswithpreviouscost-effectivenessanalyses(CEAs)(e.g.Manseletal. [17] ),itwasassumedthatthecarryover effectcontinuedfortheperiodbetweenyears9and10.Thisassumptionwasbasedonthecontinuingdivergenceoftherecurrencecurves Adverse Events, Withdrawals The probability of AEs was derived from the ATAC trial [8, 10] . Key probabilitiesforAEandwithdrawalratesusedinthemodel,withdistributions and sources, are presented in table 1. Based on expert opinion and on observations from ATAC 100, it was assumed that most treatment-related AEs and SAEs occur during the 5-year treatment period. Some events could also occur after completion of treatment (e.g. endometrialcancerandthromboembolicevents),andtheriskofendometrialcancerandofthromboemboliceventswasthereforeextendedforan additional 6 months after treatment completion. All AE rates were assumed to be constant, with the exception of baseline hip fracture rates, where an age-dependent increase was assumed, calculated from data in Icksetal. [24, 25] . TheuseofAIsisassociatedwithanincreasedriskofboneloss [26] . The use of bone densitometry was not documented in the ATAC trial. Basedonexpertopinion,someanastrozolepatientswereassumedtoreceiveinitialosteoporosisscreeningand5%ofanastrozolepatientswere assumed to receive bisphosphonates for 5 years. An estimate of bone densitometryusagewasalsoincludedinthemodel(40%withbonedensi-tometryattreatmentinitiation,20%at1styearofroutinefollowup,39% inyears2-5and29%afteryear5).
SAEs and AEs could lead to withdrawal. 26.1 and 25.4% of potentially fatal AEs and 3.3 and 3.5% of other AEs led to withdrawal, for anastrozoleandtamoxifen,respectively.Inthemodel,patientswithdrawing from the initial endocrine agent switched to the alternate drug (i.e. patients receiving tamoxifen would be switched to anastrozole, or vice versa). Patients would switch only once, and only between these two drugs.
Mortality
Equalmortalityratesafterrecurrencewereusedforeachtreatment.The probabilityofdeathafterrecurrenceswastakenfromthepublishedliterature [23] . All-cause annual mortality (table 2) and general population mortality due to certain SAEs (e.g. endometrial cancer, DVT and ischemic cerebrovascular events) were obtained from national statistics ible.Inaddition,CoxHRscanbecombinedwithWeibullsurvivalcurves inordertoexpressthetreatmenteffectofanintervention.Weibulldistributions can be described with a shape parameter (gamma) and a scale parameter(lambda) [20] .
Toestimatetheparametricsurvivalequationforthetamoxifenarm, the published time-to-first recurrence Kaplan-Meier curve for the tamoxifenarmofATAC100(table1)wasused [9] .ThedataoftheKaplan-MeiercurvewerereadinusinganMSExcel-basedstatisticalapplication,andtheresultingdatasetwasanalyzedwiththestatisticalsoftware STATA10SE.TheWeibullcurveestimatedforthe100-monthfollow-up periodprovidedagoodfitfortheempiricalKaplan-Meiercurve.Theparametersusedinthecurrentmodelaredetailedintable1a-c. Theparametricsurvivalcurvefortheanastrozolearmwasderivedby combiningthebaselinesurvivalequationforthetamoxifenarmandthe publishedHRof0.76(95%confidenceinterval(CI):0.67-0.87)foranastrozoleversustamoxifen [9] .InlinewithearlierpublicationsandtoenablecomparisonswithpreviousCEAs(e.g.Manseletal. [17] ),thetreatment effect based on the Weibull curves was then extrapolated to 10 yearstocovertheremainingperiodbetween100monthsand10years.
After10years,aWeibullsurvivalcurvefittedtotheATACTTRdata -pooledacrossthetreatmentarms-wasusedtocalculatetheprobability ofrecurrencefortheyears10-25afterinitiationoftreatment.
Patientswhorecurredinthemodelhadeitheraloco-regionalrecurrenceoradistantrecurrence,basedontheproportionofthetwotypesof recurrenceintheATACtrial,andthesewereindependentoftheoccurrenceofAEs.
Probabilities of distant recurrences among all first recurrences were derivedfromthe100-monthanalysisoftheATACtrial [9] .Theanastrozolearmhadaslightlyhigherrateofdistantrecurrencesamongallfirst recurrences (305/391 = 78%) than the tamoxifen arm (357/494 = 72%), but the absolute number of distant recurrences (305 vs. 357) and of all firstrecurrences(391vs.494)washigherinthetamoxifenarm.Probabilitiesofdistantmetastasesanddeathafterlocal-regionalrecurrencewere taken from the ATAC trial (trial data on file, 60-month data cut) and fromthepublishedliterature [21] [22] [23] (table1). [34, 35] . Theutilityscoreswereassignedtothepatientsinthecorresponding health states in the model and were used to estimate the number of QALYs gained by multiplying them with the number of years patients stayedinthathealthstate.QALYswerediscountedby3%accordingto therecentIQWiGguidelines [31] .
The uncertainties in applying the utilities to a German population wereaccountedforinthesensitivityanalysis.
Sensitivity Analysis
In order to explore the uncertainty in the main model inputs, scenario analysesanddeterministicandprobabilisticsensitivityanalyseswerecarriedout.
Inthescenarioanalysis,theeffectofthediscountrateforcostandbenefitswasexploredinaccordancewiththeIQWiGguidelines [31] .Thecost effectivenessresultswerecalculatedusingadiscountrateforcostandbenefitsof0,5,7and10%inadditiontothebasecasescenarioof3%.The effectofdifferenttimehorizonswasalsoexplored,withresultsreported for5,10,15and20yearsinadditiontothebasecasescenarioof25years.
One-waydeterministicsensitivityanalyseswereprovidedforallmajor modelvariables.Forthecostandefficacyvariables,arangeof±1stand-arddeviationfromthemeanwasused,whereasthe95%CIwasexplored fortheparametersintheparametricsurvivalequations.
In the probabilistic sensitivity analysis, the incremental cost per QALY gained was calculated using a Monte Carlo simulation of 1000 runswithvaluesdrawnfromanappropriateprobabilisticdistribution(see belowforfurtherdetails),resultingin1000estimatesofexpectedcostand utility.Resultswereestimatedasmeansforcostsandeffectsseparately, togetherwithanestimateforthe95%CIsforincrementalcosts,benefits, andICERs.
Fortheprobabilisticanalysis,distributionalassumptionsforthedifferent model inputs had to be made. Beta distributions are commonly ac- [27] . Mortality rates due to hip fracture after 5 years, however, were basedonage-specificUKdata [28] asonlyoneGermanstudywasfound thatonlyreported1-yearfatalityrates(28.6%)inolderwomen(average age76years) [29] .
Resource Utilization and Costs
Resourceutilizationwasobtainedfromtheliteratureandanexpertpanel of10office-andhospital-basedbreastcancerspecialistspractisinginGermany.Thedatacapturedmanagementandmonitoringofbothinpatients andoutpatients,includingprocedures,diagnostictests,andmedications, aswellastreatmentofSAEs/AEs. Meanresourceusewasestimatedandunitcostswereappliedtoeach resourceunittoestimatetotalcosts.Costswereexpressedin2008Euros. Only direct medical costs were included and were classified into drug costs,costsofrecurrences,costsofSAEsandAEs,andfollow-upcosts (table3).
Forthemodel,itwasassumedthatfollow-upandsurveillancewiththe recommendeddiagnosticprocedureswereperformedfor10yearsaccord-ingtocurrentnationalguidelines [30] .
Drugcostswerederivedfromstandardsources(table3).Duetothe organizational setup of the health care system in Germany, outpatient andinpatientcostsarebasedondifferentcostdatabases(EBM2000plus, G-DRG2008)forinpatientservices.Costswerediscountedata3%rate peryearaccordingtotherecentIQWiGguidelines [31] .
Calculating Quality-Adjusted Life-Years
Utilityvaluesforthemodelwereobtainedfromtheliterature [18, 32, 33] (table4).
UtilitiesforthehealthstatesandthemajorityofSAEsandAEswere basedonacross-sectionalstudywith44representativepatientswithstage I or II operable invasive breast cancer who had previously received 6 monthsormoreofadjuvanthormonaltherapy [18] .Utilitiesfordifferent health states were elicited using a chained standard gamble method, a 
Sensitivity Analysis
The scenario analysis for different discount rates (table 6) showedthattheincrementalcostperQALYresultschanged onlymoderatelywhenalteringthediscountratesforcostsand ceptedtobeusedtomodeltransitionprobabilities [36] .Parametersofthe betadistributionswerecalculatedbasedonpatientnumbersinthetrial (table1).Gammadistributions,basedonmeansandstandarddeviations, wereassumedtobeagoodfitforskewedandnon-negativetotalcostdata foreachitem(table3).Theparametersforthesurvivalregressionfollow amultivariatenormaldistributionbyassumption,whiletheHRforanastrozolewasdrawnfromalog-normaldistribution.Utilityinputswereassumedtofollowabetadistribution(table4).Theoveralllevelofuncertainty in the results was expressed as a cost-effectiveness acceptability curve.ThecurveshowstheprobabilitythattheICERliesbelowaspecifiedwillingnesstopay(WTP)threshold,i.e.theprobabilitythattheinterventioniscosteffectiverelativetoagivenWTPthreshold.
Results
Effectiveness, Costs, and Cost Effectiveness Findings
Over the 25-year time horizon, anastrozole and tamoxifen wereassociatedwithmeanQALYsof10.37and10.05perpa-tient, respectively. Anastrozole was also associated with a longer projected (and discounted) overall mean survival Theresultsofthedeterministicone-waysensitivityanalysis are represented by a tornado chart ( fig. 3) . The single most importantmodelinputistheHRforrecurrence-freesurvival ofanastrozoleovertamoxifen.Varyingthisinputfrom0.67to 0.87(thebasecasevalueis0.76)decreasedtheICERtobelow R15,000/QALY($22,032)for0.67andaboveR40,000/QALY ($58,752)for0.87.Theeffectsofthemostpowerfulinputson incremental costs and benefits are shown in tables 7 and 8, respectively. Theresultsoftheprobabilisticsensitivityanalysisusinga MonteCarlosimulationof1000runsofthemodelareshown infigure4.Theresultingcost-effectivenessacceptabilitycurve ( fig.4) indicatedagreaterthan90%probabilitythatthecost per QALY gained with anastrozole would be less than R30,000($34,867)anda50%probabilitythatitwouldbeless thanR20,000($29,376).TheICERhada95%non-parametric CI of R12,567 to R46,604 per QALY gained ($18,458 to $68,451)asreflectedintheacceptabilitycurve (fig.4) .
Discussion
ThisstudyisthefirstCEAofanAIthatisbasedonextended follow-up data, taking into account the carryover effect of anastrozole,whichmaintainstheefficacybenefitsbeyondthe completionoftreatment [9] .
Inthecurrentanalysis,theuseofanastrozolecomparedto tamoxifenasadjuvanttherapyinpostmenopausalwomenwith HR+ EBC results in an improvement in survival (290 years gained)andqualityoflife(320QALYsgained)inacohortof 1000patientsoveraperiodof25years.Fortheindividualpatient, the benefits were provided at an incremental cost of R21,069perQALYgained(95%CI:R12,567toR46,604).
Theavailablelong-termclinicaldatadonotshowstatisticallysignificantOSgainswithAIs [9, 37] ,andthishasbeen discussedcontroversially [38, 39] .SerugaandTannockargue that DFS is an imperfect surrogate for OS in adjuvant trials benefits. Using a 10% discount rate instead of the 3% rate usedinthebasecase,theICERincreasedby17%.Changing thetimehorizonhadasubstantialeffectontheresults (table  6) :Whilebenefitsareaccruedatarelativelysteadyrateover the entire lifetime, the majority of the costs arise within the first5yearsoftreatment( fig.2) ,leadingtoadecreaseinthe ICERoverlongertimehorizons. The model also assumed that AEs/SAEs only occurred overtheinitial5-yeartreatmentperiod,withtheexceptionof endometrial cancer and thromboembolic events. Thus, the model treated AEs/SAEs separately in order to account for the potentially increased mortality and their effect beyond treatment.
Severalstudiesanalyzingthecosteffectivenessofanastrozolecomparedtotamoxifenwereidentified.Alltheseanalyses, however, used the 5-year completed treatment analysis datafromtheATACtrial [17, [41] [42] [43] .Karnon [44] performed areviewofseveralpublishedhealtheconomicevaluationsof AIsintheadjuvantsetting.Heidentified15separatestudies thatevaluatedAIs.Duetothecomparativelylongclinicalexperienceandtheamountofdataavailable,CEAsofanastrozole have been studied extensively. The combined results fromstudiesusingarangeofmethodologicalapproachessuggestthattheuseofAIs,includinganastrozole,asadjuvantendocrine treatment for EBC is a cost-effective alternative to current standard therapies, although their effectiveness for very-low-risktumorsremainsuncertain.ThestudybyLocker et al. evaluated the cost effectiveness of anastrozole versus tamoxifenforprimaryadjuvanttreatmentfromtheUShealth care perspective [43] . The incremental cost effectiveness for anastrozoleversustamoxifenwas$20,246perQALYgained (equivalent to R15,387, based on an exchange rate of $1 = R0.76, October 2008) and thus within the acceptable reimbursementrangeintheUS($50,000to$100,000perQALY gained).Incontrast,basedon47monthsoftrialdata,theHillnerstudyfoundamuchhigherincrementalcosteffectiveness for anastrozole at $75,900 per QALY gained (equivalent to R33,924;exchangerateof$1=R0.76,October2008) [42] .A wide range of one-way sensitivity analyses were performed which show that the results were sensitive to the risk of hip fracture. The model assumed an OR of 1.6 for hip fractures duringanastrozoletherapy,whichishigherthantheORused inlateranalyses(OR1.17).Thisleadstohigherresourcecosts bytreatmentoffractures.Otherdifferencesfromthecurrent studyincludethechoiceoftimehorizon(20years),utilityvaluesapplied,resourceuseandhandlingofAEs.However,the mainreasonforthedifferentresultsmightwellbethedifferentHRforTTR,aparameterthatwasshowninoursensitivity analysis to be the single most important model input. WhereasHillneretal. [42] usedtheTTRHRthatwasavailable at the time (HR = 0.79) [8] , the current model uses the TTR HR from the 100-month analysis (HR = 0.76) [9] . The resulting advantage in recurrence-free survival would thereforeleadtolowerICERs.
forbreastcancer.Theymaintainthat,becauseofthislackof improvementinOS,theresultsofcost-benefitanalysesinAIs are unreliable [38] . On the other hand, Cuzick argues that DFSisawell-acceptedendpointinadjuvantstudiesofbreast cancer and other good-prognosis cancers [39] . OS can no longerberegardedastheprimaryendpointfortrialsinwhich theprognosisisgood,becauseofthelargedilutionaleffectof deathfromothercauses.Furthermore,thetimefromdistant recurrence to death in patients with breast cancer is commonly2-3yearsandlonger,sothatalongerfollow-uptime will be needed to accrue enough events to provide similar powertothatachievableusingdistantrecurrence.TheEarly Breast Cancer Trialists' Collaborative Group analyzed the 5-yearand10-yeareffectsofvarioussystemicadjuvanttherapiesonbreastcancerrecurrenceandsurvival [40] .Whilethe effect on recurrence is seen during the first 5 years, most of theeffectonbreastcancermortalitycomesafterthisperiod [40] .OScanbeimproved,buttreatmentsnormallyhaverelatively small effects on mortality from other causes, which is usually high in older patients (the typical population in the largeAItrials).
Our analysis, consistent with the clinical trial results, did not assume any OS benefit and showed non-parametric CIs just overlapping at the 10-year time horizon (95% CI: tamoxifen: 7.69-7.76 life-years gained (LYG); anastrozole: 7.76-7.86 LYG) around the OS estimates for the two treatmentarms.However,over25years,anumericallylongersurvivalisachievedbyalongerTTRforpatientsonanastrozole. Inthisanalysis,itistheimprovementinrecurrence-freesurvivalandtheavoidanceoftherapycostsforlocalrecurrence and distant metastasis that underlie the cost-effectiveness ratiointheadjuvantsetting.
TheuseofaMarkovmodelrequiredseveralassumptions whichrequirejustification.First,a25-yeartimehorizonwas chosen in order to consider the long-term benefits of treatment, including the carryover effect. This time horizon also implies that by the end of the 25-year time frame most patientsinthemodelwouldhavedied.Giventhatasubstantial proportionofthecostsaccrueswithintheinitial5-yeartreatmentperiod(e.g.drugacquisitioncosts,etc.)whereasthesurvivaleffectsoccurforatleastanotherfouryearsbasedonthe current data [9] , the ICER of R21,069 per QALY gained would be lower over longer time horizons and higher over shortertimehorizons.Totestfortheeffectofassumingacarryovereffectextendingbeyondthetrialtimehorizon,anadditional scenario was run where anastrozole did not have a recurrencebenefitcomparedtotamoxifeninyears9and10. The resulting ICER (R 24,319 per QALY) was not substantiallyhigherthanthebasecaseresult.
Another potential limitation is that some inputs for the model (e.g., estimates for resource use, definition of treatment, etc.) are based on clinical expert opinion. A better source of information would have been a national database linked to diagnosis or resource use data collected alongside Firstly,therearedifferencesbetweentheGermanhealthcare system (e.g. general organizational structure, costs, resource use, etc.) and those of other countries for which CEAs for anastrozolehavebeenperformed [46] .Secondly,thecreation of a the German health technology assessment institute (IQWiG)withitsmandatetoperformHTAsfornewhealth careinterventionsrequiresnationalCEAsthatarebasedon nationaldata.Theresultsofthecurrentmodelandofprevious cost effectiveness studies from other countries suggest thattheunderlyingbenefitsofanastrozoleinthetreatmentof postmenopausalwomenwithER+EBCtranslateintoacost effectivenessthatislargelyconsistentamongdifferenthealth caresystems.AcomparisonofthecosteffectivenessofdifferentAIsbasedonclinicaldatafromadirectcomparison(e.g. anastrozoleandletrozoleintheongoingFemaraversusAnastrozoleClinicalEvaluation(FACE)trial)wouldbedesirable in order to gain further insight into the cost effectiveness of AIsinpatientswithHR+EBC.
Conclusions
Anastrozolehasbeendemonstratedtobeclinicallyeffective andwelltoleratedbypostmenopausalwomenwithHR+EBC undergoing adjuvant endocrine therapy. The current study showsthat,basedonlong-termfollow-updata,itrepresentsa cost-effectivealternativetotamoxifenforthispatientpopulationinGermany.
